Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Dr. Suzette Delaloge Receives the Grand Prix de la Recherche Ruban Rose
A medical oncologist at Gustave Roussy and director of the personalised prevention program Interception, Dr. Suzette Delaloge has been honoured by the Ruban Rose Association for her research aimed at developing a saliva test capable of detecting early signs of breast cancer.
Published on
Dr. Suzette Delaloge, an international expert in breast cancer and personalised prevention, received the Grand Prix de la Recherche Ruban Rose on Thursday, January 16, at the French National Assembly.
This prestigious award, endowed with €350,000, supports an innovative research project she is leading. It aims to identify early warning signals, detectable at least three years before the onset of the disease, which could predict the occurrence of breast cancer.
"We will analyse the saliva of 200 women who have developed breast cancer as part of our large international study, MyPeBS, and compare it to the saliva of 200 women with the same initial characteristics but who did not develop the disease," explains Dr. Delaloge. "The goal is to identify a profile of genetic modifications in salivary DNA (including methylation) associated with the development of breast cancer in the following years," she adds.
Saliva tests have the advantage of being non-invasive and cost-effective. Ultimately, this research program aims to develop a saliva-based prevention test focused on breast cancer, which could be implemented across France.
"Like many oncologists, my motivation is intrinsic," says Dr. Delaloge. "What drives us, what fuels these programs, what continuously pushes us to go further is the desire to prevent cancer from occurring, to ensure it is diagnosed earlier, and if cancer does develop, to improve treatments and increase the chances of recovery," she continues.
This project is part of the Interception program, conceived by Dr. Delaloge and launched in 2021. Interception is based on a comprehensive approach to personalised prevention. It has already been applied to several pathways tailored to specific cancer types or risk factors. In 2024, the first Interception pathways were introduced in several partner centres across France, with more set to open in mainland France and overseas territories in 2025.
Last news
-
Nuclear medicine: DART, a pioneering platform for the development of alpha therapy
Developed through a partnership between Gustave Roussy and the Paris-Saclay Cancer Cluster, the DART project aims to provide industry partners with a centre of excellence spanning preclinical, clinical and translational research to support the development of alpha therapy. This innovative nuclear medicine approach can destroy cancer cells more powerfully than standard approaches while reducing damage to surrounding healthy cells.
-
Gustave Roussy at the ESMO 2026 Congress
The European Society for Medical Oncology (ESMO) is holding its annual congress from 23 to 27 October in Madrid, Spain. This major international event provides oncologists and researchers from around the world with an opportunity to present the latest findings from clinical studies aimed at improving cancer care and deepening our understanding of the disease. Once again, this year, physicians and researchers from Gustave Roussy have contributed to several dozen studies that will be presented during the five-day congress.
-
5 questions with Dr François-Xavier Danlos about therapeutic cancer vaccines
Therapeutic cancer vaccines are making significant progress in clinical development. The ESMO Congress, which begins on 23 October, will provide an opportunity to learn about new data on a therapeutic vaccine against melanoma. However, there are major differences between vaccines traditionally used to prevent disease and therapeutic cancer vaccines. Dr François-Xavier Danlos, a medical oncologist in Gustave Roussy’s Drug Development Department and a specialist in immunotherapy development, explains.
-
ADCs: Two Landmark Publications in Cancer Cell and Nature Medicine Showcase Gustave Roussy's Expertise
In less than two months, researchers and clinicians from Gustave Roussy have contributed to two major publications on Antibody-Drug Conjugates (ADCs) in Cancer Cell and Nature Medicine. Together, these papers provide both a comprehensive overview of current knowledge and a strategic vision to accelerate the development of the next generation of these innovative therapies.
